Cardiovascular risk, will ezetimibe IMPROVE-IT?

After quite a long time on the market, the first evidence supporting the use of ezetimibe to reduce CV events became available. The IMPROVE-IT study followed a very large cohort of very high-risk individuals for a very long time to demonstrate a small, yet significant, reduction and a composite CV outcome. I am not particularly impressed, and would probably only use it for a restricted number of patients, but I am rather curious on how others see the data.    
Source: Doc2Doc BMJ Cardiology - Category: Cardiology Authors: Source Type: forums